徐细明 - 武汉大学

个人简介

教育履历 1995.09-2000.06咸宁医学院获临床医学学士学位 2000.09-2003.06武汉大学第一临床学院内科学硕士研究生获硕士学位 2003.09-2006.06武汉大学第一临床学院内科学博士研究生获博士学位工作履历 2006.07-2007.12武汉大学人民医院肿瘤中心工作主治医师 2008.01-2012.12武汉大学人民医院肿瘤中心工作副主任医师、硕士生导师 2009.07-2010.06美国佐治亚大学肿瘤学博士后 2013.01-2019.12武汉大学人民医院肿瘤三科主任医师、副教授、硕士生导师 2020.01-2020.12 武汉大学人民医院肿瘤三科主任医师、副教授、博士生导师

研究领域

1.消化系统肿瘤基础与临床 2.肿瘤的个体化治疗、靶向治疗和免疫治疗

近期论文

查看导师新发文章（温馨提示：请注意重名现象，建议点开原文通过作者单位确认）

Hu X, Zhu H, He X, Chen J, Xiong L, Shen Y, Li J, Xu Y, Chen W, Liu X, Cao D, Xu X*. The application of nanoparticles in immunotherapy for hepatocellular carcinoma. J Control Release. 2023 Mar;355:85-108. Weng Q, Chen M, Li M, Zheng YF, Shao G, Fan W, Xu XM*, Ji J. Global microarray profiling identified hsa_circ_0064428 as a potential immune-associated prognosis biomarker for hepatocellular carcinoma. J Med Genet. 2019 Jan;56(1):32-38. Fan L, Li Y, Chen JY, Zheng YF, Xu XM*. Immune checkpoint modulators in cancer immunotherapy: Recent advances and combination rationales. Cancer Lett. 2019;456:23-28. Wang YG, Zheng DH, Shi M, Xu XM*. T cell dysfunction in chronic hepatitis B infection and liver cancer: evidence from transcriptome analysis. J Med Genet. 2019;56(1):22-28. Zhang X, He X, Li Y, Xu Y, Chen W, Liu X, Hu X, Xiong L, Xu X*. MXD3 as an Immunological and Prognostic Factor From Pancancer Analysis. Frontiers in molecular biosciences, 2021, 8:702206. Xu Y, He X, Deng J, Xiong L, Li Y, Zhang X, Chen W, Liu X, Xu X*. Comprehensive Analysis of the Immune Infiltrates and PD-L1 of m(6)A RNA Methylation Regulators in Hepatocellular Carcinoma. Frontiers in cell and developmental biology, 2021, 9:681745. Li Y, He X, Zhang X, Xu Y, Wu Y, Xu X*. Immune-related microRNA signature for predicting prognosis and the immune microenvironment in hepatocellular carcinoma. Life Sci, 2021, 265:118799. Li Y, He X, Zhang X, Xu Y, Chen W, Liu X, Xu X*. RMI2 is a prognostic biomarker and promotes tumor growth in hepatocellular carcinoma. Clinical and experimental medicine, 2021. Li Y, He X, Fan L, Zhang X, Xu Y, Xu X*. Identification of a novel immune prognostic model in gastric cancer. Clin Transl Oncol, 2021, 23(4): 846-855.